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Abstract
Aims To examine the short- and long-term cost-effectiveness of intensive multifactorial treatment compared with
routine care among people with screen-detected Type 2 diabetes.
Methods Cost–utility analysis in ADDITION-UK, a cluster-randomized controlled trial of early intensive treatment in
people with screen-detected diabetes in 69 UK general practices. Unit treatment costs and utility decrement data were
taken from published literature. Accumulated costs and quality-adjusted life years (QALYs) were calculated using
ADDITION-UK data from 1 to 5 years (short-term analysis, n = 1024); trial data were extrapolated to 30 years using
the UKPDS outcomes model (version 1.3) (long-term analysis; n = 999). All costs were transformed to the UK 2009/10
price level.
Results Adjusted incremental costs to the NHS were £285, £935, £1190 and £1745 over a 1-, 5-, 10- and 30-year time
horizon, respectively (discounted at 3.5%). Adjusted incremental QALYs were 0.0000, – 0.0040, 0.0140 and 0.0465
over the same time horizons. Point estimate incremental cost-effectiveness ratios (ICERs) suggested that the intervention
was not cost-effective although the ratio improved over time: the ICER over 10 years was £82 250, falling to £37 500
over 30 years. The ICER fell below £30 000 only when the intervention cost was below £631 per patient: we estimated
the cost at £981.
Conclusion Given conventional thresholds of cost-effectiveness, the intensive treatment delivered in ADDITION was
not cost-effective compared with routine care for individuals with screen-detected diabetes in the UK. The intervention
may be cost-effective if it can be delivered at reduced cost.
Diabet. Med. 32, 907–919 (2015)
Introduction
Type 2 diabetes is associated with increased risk of costly
macro- and microvascular complications [1,2]. Treating
diabetes accounts for over 10% of the UK National Health
Service (NHS) budget, and the condition exerts a heavy burden
on people with diabetes and on those who care for them [3].
There are a number of treatment options for individuals
with established Type 2 diabetes. National Institute for
Health and Care Excellence (NICE) guidelines recommend
structured lifestyle interventions focusing on diet, physical
activity and smoking cessation as the first line of treatment,
followed by pharmacological management of cardiovascular
risk factors [4–6]. Intensive multifactorial treatment of
individuals with established diabetes reduces the risk of
cardiovascular events and premature death by 50% and is
cost-effective relative to other preventive interventions [7,8].
With the advent of national programmes, such as the UK
Health Checks [9,10], many people will be diagnosed with
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diabetes earlier in the disease trajectory. Less is known about
the effectiveness and cost-effectiveness of intensive treatment
among these newly diagnosed patients. The balance of
benefits, harms and costs of intensive treatment may be
different among individuals with screen-detected diabetes
compared with those with clinically diagnosed and long-
standing diabetes.
The ADDITION–Europe study was a cluster-randomized
trial of the effect of intensive multifactorial treatment
compared with routine care on cardiovascular risk over
5 years among individuals with screen-detected Type 2
diabetes [11]. The intervention was associated with small,
but significant increases in cardioprotective treatment, and in
turn, a non-significant 17% relative risk reduction in the
incidence of a composite cardiovascular endpoint [12]. We
report the short-term (1- to 6-year within-trial analysis) and
long-term (10–30 years based on decision modelling) cost-
effectiveness of the intervention in the UK from a UK payer
(NHS) perspective.
Methods
The ADDITION–Europe trial (NCT 00237549) consisted
of two phases – a screening programme and a pragmatic
cluster-randomized controlled trial comparing the effects of
intensive multifactorial therapy with routine care among
individuals with screen-detected Type 2 diabetes [11,12].
This analysis used data from the two UK centres (Cam-
bridge and Leicester) included in the ADDITION trial.
Briefly, participants aged 40–69 years, without known
diabetes registered with 69 general practices were invited
to stepwise screening. In total, 1026 (Cambridge 867 and
Leicester 159) eligible participants with screen-detected
diabetes agreed to take part in the treatment phase of the
trial. General practitioners (GPs) excluded those with an
illness with a life expectancy of less than 12 months, or
who were housebound, pregnant or lactating, or with
psychological or psychiatric problems that were likely to
invalidate informed consent. This analysis focused on the
treatment phase of the trial. Participants were treated
according to the group to which their practice had been
allocated: intensive treatment or routine care. Group
allocation was concealed from participants throughout the
trial. The study was approved by local ethics committees in
each centre. All participants provided written informed
consent.
Description of comparators
In the routine care group, participants with screen-detected
diabetes received usual diabetes care through the UK NHS
according to current recommendations [13–15]. Practices
received additional funding equivalent to two 10-min and
one 30-min consultation with a GP and four 15-min nurse
appointments per patient per year for 3 years. These are
routine NHS care costs and are not therefore included in the
cost-effectiveness analysis.
In the intensive treatment group, additional features were
added to educate and support GPs, practice nurses and
participants in target-driven management of diabetes. The
intervention was delivered in general practice in Cambridge
and in peripatetic community clinics in Leicester. Detailed
information can be viewed on the ADDITION website
(www.addition.au.dk).
Briefly, in Cambridge, the intensification of diabetes
management was promoted through the addition of a
number of features to existing diabetes care. These included
funding to facilitate more frequent contact between patients
and practitioners and a practice-based academic detailing
session conducted by a local diabetologist and a GP opinion
leader. Interactive practice-based audit and feedback sessions
were organized around 6 and 14 months after the initial
education session and annually thereafter. Practice nurses
were provided with theory-based education materials to give
to participants in order to provide a shared framework for
discussion of the causes, consequences and treatment of
diabetes. Participants were encouraged to lose weight,
increase their physical activity, avoid excessive alcohol
intake, take their medication regularly, self-monitor their
blood glucose level if given a glucometer by their practice,
and attend annual health checks. Participants who smoked
were encouraged to stop. GPs were also recommended to
refer patients to a dietician.
In Leicester, care was organized and delivered by a core
team of specialist practitioners (consisting of a doctor, nurse
and dietician) within peripatetic community clinics. Early
participation in structured education for newly diagnosed
people with Type 2 diabetes (the DESMOND programme
[16]) was encouraged and dietary support offered. DES-
MOND is a group education programme delivered by
registered healthcare professionals, supported by a quality
assurance component of internal and external assessment to
ensure consistency of delivery. The programme is 6 h long,
What’s new?
• Existing evidence suggests that intensive multifactorial
treatment of individuals with established diabetes
reduces the risk of cardiovascular events by 50% and
is cost-effective relative to other preventive interven-
tions.
• Less is known about the cost-effectiveness of treatment
earlier in the disease trajectory.
• Under conventional thresholds of cost-effectiveness,
interventions to promote intensive multifactorial treat-
ment were not cost-effective compared with routine
care for individuals with screen-detected diabetes in the
UK.
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deliverable in either one full day or two half-day equivalents,
and facilitated by two educators. Learning is elicited rather
than taught, and most of the curriculum focuses on lifestyle
factors, such as food choices, physical activity and cardio-
vascular risk factors. The programme encourages partici-
pants to consider their own personal risk factors and, in
keeping with theories of self-efficacy, to choose a specific
achievable goal to work on.
For both centres, treatment algorithms were based on
trial data demonstrating the benefits of intensive treatment
of cardiovascular risk factors in people with diabetes
[8,17,18]. GPs were advised to consider prescribing an
angiotensin-converting enzyme inhibitor to participants
with a blood pressure ≥ 120/80 mmHg and a previous
cardiovascular event or at least one other cardiovascular
risk factor [17]. The remainder of the intervention was
based on the stepwise regimen from the Steno–2 study [8]
aimed at optimizing hyperglycaemia, hypertension, dyslip-
idaemia and microalbuminuria. GPs were also advised
to consider prescribing 75 mg of aspirin daily to all patients
without specific contraindications. The intensive treat-
ment protocol was revised after publication of the Heart
Protection Study [19] to include a recommendation to
prescribe a statin to all individuals with a cholesterol level
of ≥ 3.5 mmol/l.
Measurement and endpoints
Health assessments at baseline and 5 years included bio-
chemical, anthropometric and questionnaire measures, and
were undertaken by centrally trained staff following standard
operating procedures blind to study group allocation. Stan-
dardized self-report questionnaires were used to collect
information on sociodemographic characteristics (education,
employment, and ethnicity) and lifestyle habits (smoking
status, alcohol consumption). Changes in biochemical mea-
sures and medication from baseline to 5-year follow-up have
been reported previously [12]. Individuals were followed for
a mean of 5.0 (SD 1.1) years. The primary outcome was time
to cardiovascular event after diagnosis of diabetes, including
cardiovascular mortality, cardiovascular morbidity (non-
fatal myocardial infarction and non-fatal stroke), revascu-
larization and non-traumatic amputation. All events were
independently adjudicated by two members of a local
endpoint steering committee, blind to group allocation
according to an agreed protocol using standardized case
report forms.
Costs
Costing comprised the cost of delivering the intervention
itself plus the routine cost to the NHS of treating diabetes
and diabetes-related events observed in the trial. All costs
were calculated in GBP (£) and monetary values were
transformed to the 2009/10 UK national level using the
Hospital & Community Health Services (HCHS) Pay and
Prices Index [20,21].
Cost of delivering the ADDITION intervention
Costs of delivering the intervention included: (1) materials,
encompassing design, consultation meetings with health
professionals regarding development and production; (2)
practitioner and patient meetings, which included the costs
of delivering the meetings, consultant and educator time, and
doctors and nurse time; and (3) extra patient consultations
and treatment (including prescription of cardio-protective
medication and glucometers with strips, Table 1). The unit
cost of doctor, nurse and other health professional time was
obtained from standard UK unit cost references [20,21]. The
volume of resources used was obtained from the ADDITION
study protocol and relevant trial documents. Some costs were
estimated from internal accounting during the trial. The cost
for extra prescriptions in the intensive treatment group
(compared with the routine care group) was established in
treatment algorithms in 2001 at the beginning of ADDI-
TION study as compensation to GPs and was transformed to
2009/10 prices. Intervention costs were different in Cam-
bridge and Leicester and were averaged for the purposes of
the cost-effectiveness analysis. For the long-term analysis, we
assumed the additional prescription costs in the intervention
arm would continue to be incurred each year.
Cost of treatment of diabetes and diabetes-related
complication treatment
Unit treatment costs were obtained from published literature
(Table 2). We collected the annual treatment cost of Type 2
diabetes without complications and Type 2 diabetes-related
complications, in the year of the event and in subsequent
years. We counted both inpatient (cost of admissions to
hospital either as a day case or as an inpatient for one or
more nights) and non-inpatient costs (cost of all home, clinic
and telephone contacts with GPs, nurses, podiatrists, opti-
cians and dieticians, and with eye and other hospital
outpatient clinics) from the UK Prospective Diabetes Study
(UKPDS) [22] from which the majority of treatment costs
used in this study were taken. In the short-term within-in
trial cost-effectiveness analysis and the long-term modelling
analysis we used an additive method to sum the annual costs
of multiple complications.
Utility decrement
We collected published utility decrement data to calculate
quality-adjusted life years (QALYs) as the health outcome
measurement for diabetes without complications and diabe-
tes with complications including ischaemic heart disease,
myocardial infarction, heart failure, stroke, revasculariza-
tion, amputation, blindness and renal failure, from published
ª 2015 The Authors.
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literature (Table 2) [24]. The majority of these utility data
were taken from the UKPDS based on EQ5D measurement
[25]. The same value was assigned to the year of the event
and for subsequent years. For patients with multiple events,
the additive method was used where we summed utility
decrements from each event.
Short-term cost-effectiveness analysis
We calculated the accumulated costs and QALYs for every
year from diabetes diagnosis based on observed events
(myocardial infarction, stroke, revascularization and ampu-
tation) in the ADDITION trial. Both costs and QALYs
incurred after the first year were discounted at 3.5% per
annum, in line with current UK guidelines [26]. In order to
adjust for baseline imbalances, we used ordinary least
squares regression analyses to calculate cost and QALYs as
a function of intervention group (routine care/intensive
treatment), treatment centre (Cambridge/Leicester), age at
diagnosis, gender and HbA1c at baseline. Adjusted incre-
mental treatment costs and QALYs were reported as means
and 95% confidence intervals.
Long-term modelling cost-effectiveness analysis
We used the UKPDS outcomes model (version 1.3) to
perform long-term modelling analysis [27], because it is
derived from a UK population and focuses on cardiovascular
complications. We previously undertook a validation analy-
sis [28] and concluded that the model provided a reasonable
prediction of the incremental event rate although the UKPDS
model tended to overestimate the absolute event rates.
The UKPDS outcomes model predicts future events year by
year, based on a series of risk equations derived from the
initial UKPDS cohort: in general, risk equations to predict
whether an event occurs in year t are a function of the
baseline value, years since diagnosis of diabetes and the value
of the risk factor in the previous year [23]. Information from
ADDITION trial participants at baseline was entered into
the UKPDS outcomes model including age at diagnosis, sex,
ethnicity, duration of diabetes, weight, height, smoking
status, systolic blood pressure, HbA1c, total cholesterol,
HDL-cholesterol and years since pre-existing CVD events.
Values of smoking status, systolic blood pressure, HbA1c,
total-cholesterol and HDL-cholesterol were also included
from measurements taken at one and five-year follow-up. For
the years in between (2, 3 and 4) and for future years, the risk
factor values were simulated by the UKPDS outcomes risk
equations, i.e. left to propagate through the long-term model.
Data on atrial fibrillation, peripheral vascular disease,
ischemic heart disease, congestive heart failure, amputation,
blindness and renal failure at diagnosis were not collected in
the ADDITION study. Given that all participants were newly
diagnosed, all values were set to zero for these variables.
To deal with missing data in ADDITION-UK, multiple
imputation was applied using the Markov chain Monte
Carlo method assuming an arbitrary missing pattern [29,30].
A multivariate normal distribution was used to impute
missing values of weight, height, smoking status, cholesterol,
HDL, systolic blood pressure and HbA1c. In the UKPDS
outcomes model, the required ethnicity values were White
Caucasian, Afro-Caribbean and Asian–Indian. There were
some unknown or unclassifiable values, e.g. mixed
White + African, mixed White + Asian in ADDITION-UK.
It was not suitable to replace these using multiple imputa-
tion, so we excluded these participants from the analysis
(n = 25). After imputation, if the imputed HDL value was
higher than the cholesterol value (which was logically
impossible) we assumed that HDL = cholesterol – 0.1 (five
cases at baseline; one case at five-year follow-up). Five
imputations were taken for each participant and we com-
bined results with Rubin’s rules [31,32].
Using the UKPDS outcomes model we performed a
patient-level modelling analysis on time horizons of 10, 20
and 30 years with a discount rate of 3.5%. We report the
30 years simulation as the main result. For each time
horizon, 1,000 inner loops and 100 bootstraps were
conducted. Means and confidence intervals at the patient
Table 2 Unit cost (£, 2009/10 UK national level) and utility decrement for diabetes and diabetic complications
Year of event Subsequent years
Fatal Non-fatal Ref. Utility decrement Ref.
Type 2 diabetes – 494.5 494.5 [22] –0.220 [45]
IHD – 3 558.4 1 175.2 [22] –0.090 [24]
MI 2 295.6 6 861.8 1 129.8 [22] –0.055 [24]
Heart failure 3 968.4 3 968.4 1 391.1 [22] –0.108 [24]
Stroke 5 786.8 4 196.9 793.4 [22] –0.164 [24]
Revascularisation – 4 943.1 316.3 [46] –0.059 [46]
Amputation 13 664.2 13 664.2 788.7 [22] –0.280 [24]
Blindness – 1 791.7 758.9 [22] –0.074 [24]
Renal failure 30 599.2 30 599.2 30 599.2 [45] –0.263 [24]
CVD death 3 724.3 – – [46] –
Costs extracted from the UKPDS study were based on participant hospital records and survey of 3488 UKPDS participants in 1996–97 from
which inpatient and outpatient costs were predicted [22] and updated to 2009/10 price year.
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level were used to conduct a further bootstrap analysis,
adjusting for centre, age at diagnosis, gender and HbA1c at
baseline as per the short-term analysis. Incremental cost-
effectiveness ratios (ICER) for the 10-, 20- and 30-year
simulations were reported.
Decision uncertainty is illustrated with a scatter plot of
incremental cost–QALY pairs and the cost-effectiveness
acceptability curve (CEAC) [34]. One-way sensitivity analy-
ses were performed on treatment costs ( 10%), utility
decrements ( 10%) and the discount rate (0%, 5%) using
the 30-year simulation data with the results shown as a
tornado diagram [35]. We also explored two scenarios with
an intervention cost of £750 (~ 3/4 cost) and £500 (~ 1/2
cost) to represent lower set-up costs (e.g. making use of
previously designed materials).
Statistical analyses of within-trial data were performed
using Statistics Analysis System (SAS, version 9.3). Analysis
of long-term modelled scenarios was conducted using the
UKPDS model and Microsoft Excel. This manuscript was
prepared according to the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) guidelines [36].
Results
Among 1026 participants in ADDITION-UK trial, 2 people
withdrew and 25 were excluded from the modelling analysis
due to unknown or unclassifiable ethnicity. Thus, 1024
individuals were included in the short-term cost-effectiveness
analysis and 999 individuals in the long-term modelling
analysis.
Baseline characteristics of the study groups were well
matched (Table 3). Mean age at diagnosis was slightly higher
and mean cholesterol slightly lower in the intensive treatment
group compared with the routine care group. The proportion
of participants with a Caucasian ethnicity was higher in the
intensive group.
The total cost of delivering the intensive treatment
intervention in ADDITION-UK over 5 years was
£502 974, equating to a cost per person of £981 (£339 for
materials and preparatory meetings, £370 for extra patient
consultations and £262 for extra treatments). Cost by centre
was £412 595 (£913 per person) in Cambridge and £90 379
(£1482 per person) in Leicester.
After a mean of 5 years (SD 1.1) of follow-up, there were
large increases in the prescription of cardioprotective treat-
ment and small, but significant, improvements in cardiovas-
cular risk factors in favour of the intervention group (data
not shown). The incidence of first cardiovascular event was
7.2% (13.5 per 1000 person-years) in the intensive treatment
group and 8.5% (15.9 per 1000 person-years) in the routine
care group [hazard ratio (HR) 0.83, 95% confidence interval
(CI) 0.65 to 1.05] [12].
Short-term cost-effectiveness analysis
There were no statistically significant differences in cumula-
tive QALYs over any time horizon from 1 to 5 years
(Table 4). The cumulative incremental cost to the NHS
(intervention cost and other expenditure incurred as a result
of cardiovascular complications) ranged from £285.30 over a
1-year horizon to £934.90 over 5 years (discounted at
3.5%). Because intensive treatment was both more costly
and led to virtually zero incremental health gain compared
with routine care over the first 5 years, intensive treatment of
people with screen-detected Type 2 diabetes was not cost-
effective in the short-term.
Long-term cost-effectiveness analysis
Intensive treatment was associated with positive incremental
QALYs (0.0465 by 30 years, statistically significant at
20 years and beyond). The incremental cost of intensive
treatment versus routine care at 10, 20 and 30 years also
increased over time to £1745 at 30 years, yielding point
estimate ICERs of £82 250 at 10 years, falling to £35 000 at
20 years and increasing slightly to £37 500 at 30 years. The
unadjusted results suggest a lower point estimate QALY gain
in the intensive treatment arm, which is reversed once
adjustment is made for baseline differences. The cumulative
incidences of complications, death due to diabetes and to
other-causes are reported in Table 5. At 30 years, there were
trends towards reduced stroke, myocardial infarction, is-
chaemic heart disease, amputation, renal failure and death
due to diabetes, but trends towards increased heart failure,
blindness and death due to other causes. The result suggests
that whilst cost-effectiveness improves over time, it is still
above commonly accepted thresholds [26] even over a 30-
year time horizon (Fig. 1).
Analysis of uncertainty
Uncertainty and sensitivity analyses were performed on the
predicted 30-year results. The cost-effectiveness plane based
on bootstrap sampling (Fig. 2) shows the scatter plot of cost
Table 3 Baseline characteristics of the ADDITION-UK trial cohort
Routine
care group
Intensive
treatment group
N 511 513
Mean age (SD), years 60.1 (7.5) 61.1 (7.2)
Female sex, % 40.7 36.6
Caucasian ethnicity, % 86.7 91.8
Current smoker, % 18.0 17.7
Mean BMI (SD), kg/m2 33.0 (5.9) 33.1 (5.6)
Mean total cholesterol
(SD), mmol/l
5.5 (1.2) 5.3 (1.1)
Mean HDL (SD), mmol/l 1.2 (0.3) 1.2 (0.4)
Mean systolic blood
pressure (SD), mmHg
143.1 (19.4) 142.0 (20.1)
Mean HbA1c (SD), % 7.3 (1.7) 7.3 (1.7)
912
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine Cost effectiveness of early intensive multifactorial treatment  L. Tao et al.
and QALY pairs under the base case and two alternative
scenarios with lower intervention cost. In the CE plane, we
included three intervention costs: £981, £750 and £500.
Under these scenarios, 30-year point estimate ICERs are
£37 503, £32 550 and £27 178. The cost at which the ICER
is £30 000 is £631. If the intervention could be delivered for
this per patient or less, then the intervention may be
considered cost-effective.
Under all three scenarios, the majority of points are in the
NE quadrant, suggesting that the intensive treatment arm is
nearly always both more expensive and more effective
(generates more QALYs) than routine care, although the
proportion of the probability mass in the NW quadrant
suggests there is greater uncertainty around whether incre-
mental QALYs are positive. The probability of cost-effec-
tiveness according to the three different treatment costs is
51.1, 60.9 and 70.4% at a £20 000 threshold, and 65.1, 71.1
and 77.0% at £30 000 threshold respectively (Fig. 3).
One-way sensitivity analyses varying unit treatment costs,
utility decrements and discount rates showed that the
discount rate had the biggest impact on the ICER, whereas
the impact of utility decrements and treatment costs was
minimal (Fig. 4).
Discussion
We report the short- and long-term cost-effectiveness of
promotion of intensive multifactorial treatment compared
to routine care for people with screen-detected Type 2
diabetes. Cumulative costs and QALYs over a time horizon
of 1 to 5 years indicated that intensive treatment was not
cost-effective in the short-term. This result may be linked to
the finding that clinically important improvements in
cardiovascular risk factors were observed in both study
groups between baseline and follow-up [12]. Modest, but
statistically significant differences between groups in the
reduction of HbA1c, blood pressure and cholesterol
favoured the intensive treatment group. The trial was
undertaken during a time of improvements in the delivery
of diabetes care in general practice, e.g. the introduction of
the Quality and Outcomes Framework, which might have
reduced the achievable differences in treatment and risk
factors between groups. In the long-term modelling analysis,
the 30 years simulated ICER was above the recommended
UK NICE threshold (£20 000 to £30 000 per QALY) [26],
suggesting that interventions to promote delivery of inten-
sive multifactorial treatment in the ADDITION-UK study
were not cost-effective compared with routine care in the
long term.
The intervention only becomes cost-effective if it can be
delivered at a cost of less than £631 per participant: we
estimated the average cost per participant at £981 over
5 years. However, this figure may overestimate the cost to
replicate the intervention because trial materials would not
require complete redevelopment (although some adaptationTa
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to local needs would be likely) and alternative approaches to
influencing practitioner behaviour, such as point-of-care
reminders and decision aids, might be cheaper than practice
visits by specialists. Furthermore, treatment costs were based
on payments made to GP practices according to expected
costs from the trial treatment algorithms. These costs may
have been overestimated because GPs prescribed less med-
ication than anticipated [12].
Our finding of a general improvement in cost-effectiveness
over the long term is exemplary of the nature of preventive
treatments. Because most of the cost of such interventions is
borne ‘up front’, and chronic disease complications take a
long time to develop, health and cost benefits are usually seen
only in the long term. A key question for policy makers
therefore is whether they are prepared to consider a longer
time horizon in their decision-making.
A driver of our results compared with other studies might
be the disease stage of study participants. The ADDITION
study recruited participants detected by screening and
therefore at an early stage in the disease trajectory. Early
detection might help prevent complications in the future
directly by attenuating disease progression, but intervening
‘too early’ might be less cost-effective. For example, inter-
vening when a patient presents with diabetes-related symp-
toms may reduce the risk of an event that would otherwise
have occurred in 5 years’ time. Intervening at an earlier
Table 5 Adjusted cumulative event incidence rates and adjusted risk factors from modelling simulation for 5, 10, 20, and 30 years
Simulated
years
Routine
care
Intensive
treatment
Adjusted difference*
(Intensive treatment–
Routine care)
Standard
error
Complication Stroke 5 0.0210 0.0226 0.0009 0.0009
10 0.0554 0.0589 0.0023 0.0017
20 0.1332 0.1396 0.0041 0.0029
30 0.1647 0.1700 0.0041 0.0032
Myocardial
infarction
5 0.0667 0.0691 0.0042 0.0023
10 0.1495 0.1550 0.0080 0.0042
20 0.3125 0.3195 0.0127 0.0070
30 0.3748 0.3775 0.0132 0.0077
Ischaemic heart
disease
5 0.0323 0.0329 0.0012 0.0008
10 0.0642 0.0651 0.0019 0.0013
20 0.1197 0.1202 0.0018 0.0019
30 0.1395 0.1380 0.0018 0.0020
Heart failure 5 0.0201 0.0210 0.0005 0.0008
10 0.0612 0.0635 0.0011 0.0021
20 0.1494 0.1545 0.0001 0.0040
30 0.1851 0.1896 0.0017 0.0044
Amputation 5 0.0027 0.0028 0.0001 0.0002
10 0.0074 0.0072 0.0002 0.0003
20 0.0215 0.0210 0.0002 0.0004
30 0.0308 0.0291 0.0005 0.0005
Blindness 5 0.0183 0.0197 0.0002 0.0004
10 0.0392 0.0418 0.0006 0.0005
20 0.0734 0.0772 0.0013 0.0007
30 0.0861 0.0889 0.0012 0.0007
Renal failure 5 0.0015 0.0013 0.0002 0.0001
10 0.0047 0.0046 0.0002 0.0002
20 0.0156 0.0151 0.0005 0.0004
30 0.0227 0.0216 0.0005 0.0006
Diabetes death 5 0.0119 0.0134 0.0010 0.0018
10 0.0416 0.0450 0.0003 0.0031
20 0.1390 0.1457 0.0019 0.0042
30 0.1905 0.1950 0.0017 0.0045
Other death 5 0.0669 0.0710 0.0029 0.0016
10 0.1671 0.1776 0.0049 0.0028
20 0.4532 0.4779 0.0019 0.0037
30 0.7105 0.7240 0.0015 0.0051
Risk factor HbA1c 5 7.33 7.30 0.0060 0.0450
10 8.09 8.07 0.0116 0.0118
20 8.74 8.74 0.001 0.001
30 9.04 9.04 0.000 0.000
Systolic blood
pressure
5 138.59 137.38 1.4835 0.7578
10 141.98 141.38 0.9157 0.5457
20 143.76 143.32 0.7630 0.5569
30 144.43 143.99 0.7575 0.5578
*Adjusted for age at diabetes diagnosis, sex, baseline HbA1c and centre.
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stage, e.g. detection of impaired glucose tolerance, may
prevent an event that would not otherwise occur for
20 years. Generally, individuals and society have a prefer-
ence for benefits now rather than in the future, so would
value preventing an event in five years’ time more highly than
preventing that same event in 20 years.
Strengths and limitations
This economic evaluation used data from a large random-
ized controlled trial and the cost-effectiveness analysis
was conducted using a robust evaluation framework. We
examined cost-effectiveness outcomes both for the short-
and long-term and performed sensitivity analyses to test the
robustness of our findings. We used data derived from a UK
population with long-term CVD outcomes (the UKPDS
study) to calculate unit costs, utility decrements and
modelled CVD risk. We adjusted for centre (Cambridge/
Leicester) rather than practice site, because the intervention
differed slightly between the centres but within the same
centre practices shared standardized practitioner guidelines.
Intra-class correlation values for GP practice for the primary
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FIGURE 1 Broken line chart showing the simulated incremental cost-effectiveness ratios (ICERs) at 10, 20 and 30 years for the ADDITION-UK
intervention.
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outcome were very small in the main ADDITION-Europe
trial, supporting our decision to adjust for centre rather than
practice.
There were some limitations. First, we only focused on
macrovascular outcomes (CVD and associated acute events).
Microvascular outcomes such as retinopathy and nephropa-
thy are also important in assessing the impact of Type 2
diabetes on both quality of life and cost. Exclusion of these is
likely to underestimate the benefit from any preventative
intervention and thus underestimate the cost-effectiveness
(that is, overestimate the ICER), particularly in the longer
term as patients avoid cardiovascular disease and live with
diabetes long enough to develop microvascular complications.
Second, although the treatment protocol was identical, the
lifestyle intervention was different in Leicester and Cam-
bridge. To represent the cost of implementing an ‘ADDI-
TION-like’ intervention reflecting a degree of diversity across
the country we simply averaged the two. We did, however,
include centre in the adjusted analyses estimating incremen-
tal cost and QALYs. Results were similar when we adjusted
for cluster (GP practice) and when running analyses sepa-
rately by centre.
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FIGURE 3 Cost-effectiveness acceptability curves which show the probability of intensive treatment being more cost-effective than routine care
based on net benefit values from bootstrap samples using three different costs of delivering intensive treatment: £980.50 (blue), £750 (red) and £500
(green). The two dotted lines show the cost-effectiveness acceptability thresholds of £20 000 and £30 000 per QALY.
FIGURE 4 Tornado diagram showing the influence of changing different parameters that contribute to the ICER in long-term cost-effectiveness
modelling analysis. Choice of discount rate has the greatest impact on the ICER (higher discount rate, unit costs and lower utility decrements all
associated with higher point estimate ICER).
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Third, because the results of this study were largely driven
by data from Cambridge (n = 867 participants versus
n = 159 in Leicester), where the vast majority of participants
were Caucasian, the generalizability to other more ethnically
diverse populations must be considered with caution. How-
ever, the capacity to benefit from intensive multifactorial
treatment is probably higher given the increased risk of
diabetes and diabetes-related complications in ethnic minor-
ity groups [39].
Fourth, we used an additive method to calculate treatment
costs and utility decrements for individuals with multiple
events. This is a commonly used method, which was
applied in the UKPDS outcomes model [22,40], but it is
unclear if the cost and utility decrement of subsequent
complications should be additive or multiplicative.
Fifth, most of the equations in the UKPDS predict future
risk factors and events based on baseline values, time since
diagnosis and the value of biometrics such as HbA1c in the
previous period (year). It is an individual-level model in
which patient data are calculated individually (rather than as
mean values of a cohort). Thus, the model assumes that any
trends present at 5 years will continue into the future,
effectively assuming a continuation of the effect of the small
differences in treatment generated by the intervention at
5 years. Ten-year follow-up of the UKPDS cohort found that
although between-group differences in HbA1c and blood-
pressure were both lost within 12 months of the end of the
active phase of the study, those who had previously achieved
tighter control over HbA1c still had a lower event rate at
10 years than those who had not, whereas any benefit from a
lower blood pressure was not maintained [41,42]. Current
guidelines and practice have changed since the initiation of
the ADDITION trial, with patients recommended to receive
at least as intensive treatment as the ‘intensive’ arm. Trial
patients in the routine care arm received a higher level of
treatment than observed in ‘standard practice’, which may
have diluted the observed incremental health gain. However,
after 5 years of treatment, there was room for improvement
in the prescription of cardioprotective treatment in both
groups. Current evidence suggests that delays in treatment
intensification in people with Type 2 diabetes (clinical
inertia) are still very common.
On the cost side, the official duration of the intensive
intervention was 3 years, for which practices were reim-
bursed for additional activity and prescriptions. We pro-
jected additional prescribed drug costs in the intervention
arm over the full 30 years, under the assumption that
patients in the control arm would not increase their medi-
cation, and patients in the intervention arm would not
decrease their medication over time. We may, therefore, have
overestimated the cost of the intervention arm. Whether this
is true or not will be assessed once the 10-year follow-up data
of the ADDITION cohort are available for analysis.
Finally, although we used the most appropriate CVD risk
model available, the UKPDS outcomes model was derived
using data from an historical cohort of people with clinically
diagnosed diabetes. The ADDITION cohort included people
with screen-detected diabetes. Other studies [43,44] show
that the UKPDS outcomes model tends to overestimate
absolute CVD risk, a finding replicated in our own investi-
gation of the suitability of the UKPDS to extrapolate
ADDITION data [28]. This is unsurprising because the
UKPDS cohort collected data between 1977 and 1997, and
the treatment of diabetes and its complications has improved
substantially, leading to changes in treatment costs and
outcomes. However, for the prediction of differences
between intervention groups, the results of our validation
analysis [28] were mixed: the UKPDS model overestimated
the group difference for stroke but underestimated the
difference for myocardial infarction, albeit within ‘tolerable’
limits. In addition, the utility decrements for myocardial
infarction and stroke derived from the ADDITION-UK study
were smaller than those in UKPDS, a finding consistent with
contemporary patients receiving better care and hence
reporting higher quality of life. This underlines the impor-
tance of our sensitivity analyses, showing the robustness of
the results to changes in the input parameters. The discount
rate has the biggest impact compared with the intervention
unit cost and utility decrement.
In conclusion, promotion of intensive multifactorial treat-
ment compared to routine care for people with screen-
detected Type 2 diabetes does not appear to be cost-effective
in the ADDITION-UK study. However, the intervention has
the potential to be cost-effective if it can be delivered for
approximately £630 per patient rather than £981. Such
savings may be plausible through adaptation of pre-devel-
oped materials and economies of scale in delivery.
Funding sources
ADDITION-Cambridge was supported by the Wellcome
Trust (grant reference no: G061895); the Medical Research
Council (grant reference no: G0001164); the National
Institute for Health Research (NIHR) Health Technology
Assessment Programme (grant reference no: 08⁄116⁄300);
National Health Service R&D support funding (including the
Primary Care Research and Diabetes Research Networks);
and the National Institute for Health Research. SJG received
support from the Department of Health NIHR Programme
Grant funding scheme (RP-PG-0606-1259). The views
expressed in this publication are those of the authors and
not necessarily those of the UK Department of Health. Bio-
Rad provided equipment for HbA1c testing during the
screening phase. ADDITION-Leicester was supported by
the Department of Health and ad hoc Support Sciences; the
NIHR Health Technology Assessment Programme (grant
reference no: 08⁄116⁄300); National Health Service R&D
support funding (including the Primary Care Research and
Diabetes Research Network, and LNR CLAHRC); and the
National Institute for Health Research. MJD and KK receive
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 917
Research article DIABETICMedicine
support from the Department of Health NIHR Programme
Grant funding scheme (RP-PG-0606-1272), the NIHR Col-
laboration for Leadership in Applied Health Research &
Care (CLAHRC) and NIHR Leicester Loughborough Diet,
Lifestyle and Physical Activity Biomedical Research Centre.
Competing interests
None declared.
Acknowledgements
We gratefully acknowledge the contribution of all partici-
pants, practice nurses and general practitioners in the
ADDITION–Europe study. We are grateful to the ADDI-
TION–Cambridge independent trial steering committee [Ni-
gel Stott (Chair), John Weinman, Richard Himsworth, and
Paul Little] and to the independent endpoint committee in
the UK (Professor Jane Armitage and Dr Louise Bowman).
We thank Dr Clare Boothby (MRC Epidemiology Unit, UK)
for her assistance with data cleaning, the Diabetes Trials Unit
at Oxford University for the UKPDS outcomes model license,
and the Health Economics Group at the University of East
Anglia for methodological advice.
References
1 Arredondo A. Diabetes: a global challenge with high economic
burden for public health systems and society. Am J Public Health
2013; 103: e1–e2.
2 Liu S, Zhao Y, Hempe JM, Fonseca V, Shi L. Economic burden of
hypoglycemia in patients with Type 2 diabetes. Expert Rev
Pharmacoecon Outcomes Res 2012; 12: 47–51.
3 McInnes AD. Diabetic foot disease in the United Kingdom: about
time to put feet first. Journal Foot Ankle Res 2012; 5: 26.
4 Idris I. New NICE guideline for managing hyperglycaemia in
patients with type 2 diabetes recognised the use of newer therapies.
Diabet Obes Metab 2009; 11: 910.
5 Mathiesen ER, Damm P. Commentary from Copenhagen on the
NICE guideline on management of diabetes and its complications
from preconception to the postnatal period. Diabet Med 2008; 25:
1028–1029.
6 Walker JD.NICEGuidance onDiabetes in Pregnancy:Management
of Diabetes and its Complications from Preconception to the
Postnatal Period. NICEClinical Guideline 63. London: NICE, 2008.
7 Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M,
Parving HH et al. Cost-effectiveness of intensified versus conven-
tional multifactorial intervention in type 2 diabetes: results and
projections from the Steno–2 study. Diabetes Care 2008; 31: 1510–
1515.
8 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.
Multifactorial intervention and cardiovascular disease in patients
with type 2 diabetes. N Engl J Med 2003; 348: 383–393.
9 Khunti K, Morris DH, Weston CL, Gray LJ, Webb DR, Davies MJ.
Joint prevalence of diabetes, impaired glucose regulation, cardio-
vascular disease risk and chronic kidney disease in South Asians and
White Europeans. PloS one 2013; 8: e55580.
10 UK National Screening Committee. The UK NSC Policy on
Diabetes Screening in Adults. London: UK National Screening
Committee, 2013.
11 Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffen-
buttel BH, Rutten G et al. The ADDITION study: proposed trial of
the cost-effectiveness of an intensive multifactorial intervention on
morbidity and mortality among people with Type 2 diabetes
detected by screening. Int J Obes Relat Metab Disord 2000; 24
(Suppl 3): S6–S11.
12 Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE,
Sandbaek A et al. Effect of early intensive multifactorial therapy on
5-year cardiovascular outcomes in individuals with type 2 diabetes
detected by screening (ADDITION-Europe): a cluster-randomised
trial. Lancet 2011; 378: 156–167.
13 McIntosh AHA, Home PD, Brown F, Bruce A, Damerell A, Davis R
et al. Clinical guidelines and evidence review for Type 2 diabetes:
management of blood glucose. University of Sheffield, 2001.
14 McIntosh AHA, Home PD, Brown F, Bruce A, Damerell A, Davis R
et al. Clinical guidelines and evidence review for Type 2 diabetes:
management of blood pressure. University of Sheffield, 2002.
15 McIntosh AHA, Home PD, Brown F, Bruce A, Damerell A, Davis R
et al. Clinical guidelines and evidence review for Type 2 diabetes:
lipids management. University of Sheffield, 2002.
16 Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME,
Cradock S et al. Effectiveness of the diabetes education and self
management for ongoing and newly diagnosed (DESMOND)
programme for people with newly diagnosed type 2 diabetes:
cluster randomised controlled trial. BMJ 2008; 336: 491–495.
17 Heart Outcomes Prevention Evaluation Study Investigators. Effects
of ramipril on cardiovascular and microvascular outcomes in
people with diabetes mellitus: results of the HOPE study and
MICRO-HOPE substudy. Lancet 2000; 355: 253–259.
18 UK Prospective Diabetes Study UKPDS) Group. Intensive blood-
glucose control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with
type 2 diabetes (UKPDS 33. Lancet 1998; 352: 837–853.
19 Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection
Study Collaborative G. MRC/BHF Heart Protection Study of
cholesterol-lowering with simvastatin in 5963 people with diabetes:
a randomised placebo-controlled trial. Lancet 2003; 361: 2005–
2016.
20 Curtis L. PSSRU Inflation Indices, Secondary PSSRU Inflation
Indices. Personal Social Services Research Unit, University of Kent
at Canterbury, 2004.
21 Curtis L. Unit Costs of Health and Social Care 2010. Personal
Social Services Research Unit (PSSRU), University of Kent at
Canterbury, 2010.
22 Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of
diabetes-related complications on healthcare costs: results from the
United Kingdom Prospective Diabetes Study (UKPDS Study No.
65). Diabet Med 2003; 20: 442–450.
23 Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ
et al. A model to estimate the lifetime health outcomes of patients
with type 2 diabetes: the United Kingdom Prospective Diabetes
Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia
2004; 47: 1747–1759.
24 Clarke P, Gray A, Holman R. Estimating utility values for health
states of type 2 diabetic patients using the EQ-5D (UKPDS 62).
Med Decis Making 2002; 22: 340–349.
25 Szende A, Oppe M, Devlin N. EQ–5D Value Sets: Inventory,
Comparative Review and User Guide. Dordrecht: Springer, 2007.
26 National Institute for Health and Care Excellence. Guide to the
Methods of Technology Appraisal 2013. London: NICE, 2013.
27 Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-
dependent) diabetes mellitus by diet and physical exercise. The 6-
year Malmo feasibility study. Diabetologia 1991; 34: 891–898.
28 Tao L, Wilson EC, Griffin SJ, Simmons RK, ADDITION-Europe
Study Team. Performance of the UKPDS outcomes model for
918
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine Cost effectiveness of early intensive multifactorial treatment  L. Tao et al.
prediction of myocardial infarction and stroke in the ADDITION-
Europe trial cohort. Value Health 2013; 16: 1074–1080.
29 Rubin DB, Schenker N. Multiple imputation in health-care
databases: an overview and some applications. Stat Med 1991;
10: 585–598.
30 Yuan Y. Multiple Imputation Using SAS Software. J Stat Software
2011; 45: 1–25.
31 Rubin DB, Schenker N. Multiple imputation in health-care
databases: an overview and some applications. Stat Med 1991;
10: 585–598.
32 Rubin DB. Mutliple Imputation for Nonresponse in Surveys. New
York: Wiley, 2004.
33 Efron B. The bootstrap and Markov-chain Monte Carlo. J
Biopharm Stat 2011; 21: 1052–1062.
34 Fenwick E, Byford S. A guide to cost-effectiveness acceptability
curves. Br J Psychiat 2005; 187: 106–108.
35 Eschenbach TG. Technical Note: Constructing tornado diagrams
with spreadsheets. Eng Econ 2006; 51: 195–204.
36 Husereau D, Drummond M, Petrou S, Carswell C, Moher D,
Greenberg D et al. Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement. BMJ 2013; 346: f1049–
f1049.
37 Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell
MJ et al. Delivering the diabetes education and self management
for ongoing and newly diagnosed (DESMOND) programme for
people with newly diagnosed type 2 diabetes: cost effectiveness
analysis. BMJ 2010; 341: c4093.
38 Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G.
Methods for the Economic Evaluation of Health Care Programmes,
3rd ed. Oxford: Oxford University Press, 2005.
39 Gholap N, Davies M, Patel K, Sattar N, Khunti K. Type 2 diabetes
and cardiovascular disease in South Asians. Primary Care Diabet
2011; 5: 45–56.
40 Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP
et al. The direct medical cost of type 2 diabetes. Diabetes Care
2003; 26: 2300–2304.
41 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year
follow-up of intensive glucose control in type 2 diabetes. N Engl J
Med 2008; 359: 1577–1589.
42 Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-
term follow-up after tight control of blood pressure in type 2
diabetes. N Engl J Med 2008; 359: 1565–1576.
43 Coleman RL, Stevens RJ, Retnakaran R, Framingham Holman RR.
SCORE, and DECODE risk equations do not provide reliable
cardiovascular risk estimates in type 2 diabetes. Diabetes Care
2007; 30: 1292–1293.
44 Kengne AP, Patel A, Colagiuri S, Heller S, Hamet P, Marre M et al.
The Framingham and UK Prospective Diabetes Study (UKPDS) risk
equations do not reliably estimate the probability of cardiovascular
events in a large ethnically diverse sample of patients with diabetes:
the Action in Diabetes and Vascular Disease: Preterax and
Diamicron-MR Controlled Evaluation (ADVANCE) Study. Dia-
betologia 2010; 53: 821–831.
45 Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J et al.
Cost-effectiveness of sitagliptin-based treatment regimens in Euro-
pean patients with type 2 diabetes and haemoglobin A1c above
target on metformin monotherapy. Diabet Obes Metab 2008; 10
(Suppl 1): 43–55.
46 Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V,
Williams R et al. PROactive 06: cost-effectiveness of pioglitazone
in Type 2 diabetes in the UK. Diabet Med 2007; 24: 982–1002.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Baseline and five-year follow-up values for clinical
variables, separately by trial group in the ADDITION-UK
trial cohort; all values are mean (SD).
Table S2. Sensitivity analysis for the short term:  10% unit
treatment costs,  10% utility decrements, and 0% and 5%
discount rate.
Table S3. Sensitivity analysis for long term:  10% unit
treatment costs,  10% utility decrements, and 0% and 5%
discount rate.
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 919
Research article DIABETICMedicine
